glp-1 receptor agonists and sglt2 inhibitors in Diabetic Kidney Disease: Evolving Evidence and Clinical Application Cardiorenal Protection: Potential of SGLT2

Standards of Care in Diabetes2025

(2025) explores current evidence, challenges, and future perspectives in managing surgical patients on GLP-1R agonists

Purpose of Review This review will summarize the most contemporary trials for glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2-i) and present guidance on management and recommendations on adjunctive tapering of insulin in patients with insulin-dependent diabetes mellitus, which we term de-insulinization. Recent Findings GLP1-RA and SGLT2-i are the principal classes of diabetes medications evidencing cardiovascular benefit

DPP-4 inhibitors were introduced for the treatment of type 2 diabetes in 2006

Big thanks to our clinical team for this breakthrough innovation